Literature DB >> 33274661

Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury?

Mohammad Obeidat1, Alexandra L Isaacson1, Stephanie J Chen1, Marina Ivanovic1, Danniele Holanda1.   

Abstract

COVID-19 (from SARS-CoV-2) is the cause of an ongoing pandemic, with an increasing number of cases and significant mortality worldwide. Clinical trials and extensive studies are being conducted on a large scale for a better understanding of the pathophysiology of this disease and its effect on different organs. Several experimental treatment protocols have been introduced, in which hydroxychloroquine (HCQ) was one of the first drugs used. While patients can develop many side effects of HCQ, studies have documented a rare association of long-term HCQ treatment with zebra-like bodies in the ultrastructural examination of kidney biopsies, a finding typically seen in Fabry's disease, as well as in association with chronic HCQ use, among other drugs. We present a similar finding in the postmortem examination of a male in his early seventies with COVID-19 infection, who received five days of HCQ treatment before stopping the medication due to cardiac and renal toxicity.

Entities:  

Keywords:  Covid-19; Pandemic; acute kidney injury; acute tubular injury; hydroxychloroquine; zebra bodies

Year:  2020        PMID: 33274661     DOI: 10.1080/01913123.2020.1850966

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  5 in total

1.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  mSystems       Date:  2021-11-02       Impact factor: 6.496

2.  Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2.

Authors:  Tia A Tummino; Veronica V Rezelj; Benoit Fischer; Audrey Fischer; Matthew J O'Meara; Blandine Monel; Thomas Vallet; Ziyang Zhang; Assaf Alon; Henry R O'Donnell; Jiankun Lyu; Heiko Schadt; Kris M White; Nevan J Krogan; Laszlo Urban; Kevan M Shokat; Andrew C Kruse; Adolfo García-Sastre; Olivier Schwartz; Francesca Moretti; Marco Vignuzzi; Francois Pognan; Brian K Shoichet
Journal:  bioRxiv       Date:  2021-03-24

Review 3.  Safety profile of COVID-19 drugs in a real clinical setting.

Authors:  Mei Nee Chiu; Maitry Bhardwaj; Sangeeta Pilkhwal Sah
Journal:  Eur J Clin Pharmacol       Date:  2022-01-28       Impact factor: 3.064

4.  Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis.

Authors:  Ning An; Chen Yang; Hong-Luan Wu; Yun Guo; Xi-Jie Huang; Tong-Sheng Huang; Zhi-Hong Wu; Jing Xue; Rui-Hong Chen; Zhi-Hang Li; Qing-Jun Pan; Hua-Feng Liu
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

5.  Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.

Authors:  Tia A Tummino; Veronica V Rezelj; Benoit Fischer; Audrey Fischer; Matthew J O'Meara; Blandine Monel; Thomas Vallet; Kris M White; Ziyang Zhang; Assaf Alon; Heiko Schadt; Henry R O'Donnell; Jiankun Lyu; Romel Rosales; Briana L McGovern; Raveen Rathnasinghe; Sonia Jangra; Michael Schotsaert; Jean-René Galarneau; Nevan J Krogan; Laszlo Urban; Kevan M Shokat; Andrew C Kruse; Adolfo García-Sastre; Olivier Schwartz; Francesca Moretti; Marco Vignuzzi; Francois Pognan; Brian K Shoichet
Journal:  Science       Date:  2021-06-22       Impact factor: 47.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.